Top

Journal of Experimental & Clinical Cancer Research

Published in:

01-12-2021 | Neuroblastoma | Review

A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma

Authors: Vid Mlakar, Edouard Morel, Simona Jurkovic Mlakar, Marc Ansari, Fabienne Gumy-Pause

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Abstract

Neuroblastoma is the most common extra-cranial solid tumor in children, representing approximately 8% of all malignant childhood tumors and 15% of pediatric cancer-related deaths. Recent sequencing and transcriptomics studies have demonstrated the RAS-MAPK pathway’s contribution to the development and progression of neuroblastoma. This review compiles up-to-date evidence of this pathway’s involvement in neuroblastoma. We discuss the RAS-MAPK pathway’s general functioning, the clinical implications of its deregulation in neuroblastoma, and current promising therapeutics targeting proteins involved in signaling.

Available only for authorised users

Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369:2106–20. https://doi.org/10.1016/S0140-6736(07)60983-0.CrossRefPubMed

Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Pediatr Clin N Am. 2008;55(1):97–120, x. https://doi.org/10.1016/j.pcl.2007.10.014.CrossRef

Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3:203–16. https://doi.org/10.1038/nrc1014.CrossRefPubMed

Pastor ER, Mousa SA. Current management of neuroblastoma and future direction. Crit Rev Oncol Hematol. 2019;138:38–43. https://doi.org/10.1016/j.critrevonc.2019.03.013.CrossRefPubMed

Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362(23):2202–11. https://doi.org/10.1056/NEJMra0804577.CrossRefPubMedPubMedCentral

Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, et al. Neuroblastoma. Nat Rev Dis Primers. 2016;2(1):16078. https://doi.org/10.1038/nrdp.2016.78.CrossRefPubMed

Mlakar V, Jurkovic Mlakar S, Lopez G, Maris JM, Ansari M, Gumy-Pause F. 11q deletion in neuroblastoma: a review of biological and clinical implications. Mol Cancer. 2017;16(1):114. https://doi.org/10.1186/s12943-017-0686-8.CrossRefPubMedPubMedCentral

Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009;27:289–97. https://doi.org/10.1200/JCO.2008.16.6785.CrossRefPubMedPubMedCentral

Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455:930–5. https://doi.org/10.1038/nature07261.CrossRefPubMedPubMedCentral

10.

Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature. 2008;455:967–70. https://doi.org/10.1038/nature07398.CrossRefPubMed

11.

Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature. 2008;455:971–4. https://doi.org/10.1038/nature07399.CrossRefPubMed

12.

Caren H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J. 2008;416:153–9. https://doi.org/10.1042/bj20081834.CrossRefPubMed

13.

George RE, Sanda T, Hanna M, Frohling S, Luther W 2nd, Zhang J, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008;455(7215):975–8. https://doi.org/10.1038/nature07397.CrossRefPubMedPubMedCentral

14.

Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013;45:279–84. https://doi.org/10.1038/ng.2529.CrossRefPubMedPubMedCentral

15.

Bresler SC, Weiser DA, Huwe PJ, Park JH, Krytska K, Ryles H, et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell. 2014;26:682–94. https://doi.org/10.1016/j.ccell.2014.09.019.CrossRefPubMedPubMedCentral

16.

Eleveld TF, Oldridge DA, Bernard V, Koster J, Colmet Daage L, Diskin SJ, et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet. 2015;47:864–71. https://doi.org/10.1038/ng.3333.CrossRefPubMedPubMedCentral

17.

Tolbert VP, Coggins GE, Maris JM. Genetic susceptibility to neuroblastoma. Curr Opin Genet Dev. 2017;42:81–90. https://doi.org/10.1016/j.gde.2017.03.008.CrossRefPubMedPubMedCentral

18.

Tonini GP, Capasso M. Genetic predisposition and chromosome instability in neuroblastoma. Cancer Metastasis Rev. 2020;39:275–85. https://doi.org/10.1007/s10555-020-09843-4.CrossRefPubMed

19.

Osajima-Hakomori Y, Miyake I, Ohira M, Nakagawara A, Nakagawa A, Sakai R. Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol. 2005;167(1):213–22. https://doi.org/10.1016/S0002-9440(10)62966-5.CrossRefPubMedPubMedCentral

20.

Miyake I, Hakomori Y, Shinohara A, Gamou T, Saito M, Iwamatsu A, et al. Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines. Oncogene. 2002;21:5823–34. https://doi.org/10.1038/sj.onc.1205735.CrossRefPubMed

21.

Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, et al. Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature. 2018;555(7696):371–6. https://doi.org/10.1038/nature25795.CrossRefPubMedPubMedCentral

22.

De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, et al. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res. 2010;16:4353–62. https://doi.org/10.1158/1078-0432.CCR-09-2660.CrossRefPubMed

23.

Trigg RM, Turner SD. ALK in neuroblastoma: biological and therapeutic implications. Cancers (Basel). 2018;10. https://doi.org/10.3390/cancers10040113.

24.

Padovan-Merhar OM, Raman P, Ostrovnaya I, Kalletla K, Rubnitz KR, Sanford EM, et al. Enrichment of targetable mutations in the relapsed neuroblastoma genome. PLoS Genet. 2016;12(12):e1006501. https://doi.org/10.1371/journal.pgen.1006501.CrossRefPubMedPubMedCentral

25.

Ackermann S, Cartolano M, Hero B, Welte A, Kahlert Y, Roderwieser A, et al. A mechanistic classification of clinical phenotypes in neuroblastoma. Science. 2018;362:1165–70. https://doi.org/10.1126/science.aat6768.CrossRefPubMedPubMedCentral

26.

Shukla N, Ameur N, Yilmaz I, Nafa K, Lau CY, Marchetti A, et al. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res. 2012;18:748–57. https://doi.org/10.1158/1078-0432.CCR-11-2056.CrossRefPubMed

27.

Ireland CM. Activated N-ras oncogenes in human neuroblastoma. Cancer Res. 1989;49:5530–3.PubMed

28.

Moley JF, Brother MB, Wells SA, Spengler BA, Biedler JL, Brodeur GM. Low frequency of ras gene mutations in neuroblastomas, pheochromocytomas, and medullary thyroid cancers. Cancer Res. 1991;51:1596–9.PubMed

29.

Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007;7:295–308. https://doi.org/10.1038/nrc2109.CrossRefPubMed

30.

Eleveld TF, Schild L, Koster J, Zwijnenburg DA, Alles LK, Ebus ME, et al. RAS-MAPK pathway-driven tumor progression is associated with loss of CIC and other genomic aberrations in neuroblastoma. Cancer Res. 2018;78(21):6297–307. https://doi.org/10.1158/0008-5472.CAN-18-1045.CrossRefPubMed

31.

Li H, Yu Y, Zhao Y, Wu D, Yu X, Lu J, et al. Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling. Cancer Lett. 2019;457:129–41. https://doi.org/10.1016/j.canlet.2019.05.011.CrossRefPubMed

32.

Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54. https://doi.org/10.1038/nature00766.CrossRefPubMed

33.

Marks JL, Gong Y, Chitale D, Golas B, McLellan MD, Kasai Y, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524–8. https://doi.org/10.1158/0008-5472.CAN-08-0099.CrossRefPubMedPubMedCentral

34.

Aurtenetxe O, Zaldumbide L, Erramuzpe A, Lopez R, Lopez JI, Cortes JM, et al. DUSP5 expression associates with poor prognosis in human neuroblastoma. Exp Mol Pathol. 2018;105:272–8. https://doi.org/10.1016/j.yexmp.2018.08.008.CrossRefPubMed

35.

Esposito MR, Binatti A, Pantile M, Coppe A, Mazzocco K, Longo L, et al. Somatic mutations in specific and connected subpathways are associated with short neuroblastoma patients’ survival and indicate proteins targetable at onset of disease. Int J Cancer. 2018;143(10):2525–36. https://doi.org/10.1002/ijc.31748.CrossRefPubMed

36.

Schleiermacher G, Javanmardi N, Bernard V, Leroy Q, Cappo J, Rio Frio T, et al. Emergence of new ALK mutations at relapse of neuroblastoma. J Clin Oncol. 2014;32(25):2727–34. https://doi.org/10.1200/JCO.2013.54.0674.CrossRefPubMed

37.

Der CJ, Finkel T, Cooper GM. Biological and biochemical properties of human rasH genes mutated at codon 61. Cell. 1986;44:167–76. https://doi.org/10.1016/0092-8674(86)90495-2.CrossRefPubMed

38.

Trochet D, Bourdeaut F, Janoueix-Lerosey I, Deville A, de Pontual L, Schleiermacher G, et al. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J Hum Genet. 2004;74:761–4. https://doi.org/10.1086/383253.CrossRefPubMedPubMedCentral

39.

Mosse YP, Laudenslager M, Khazi D, Carlisle AJ, Winter CL, Rappaport E, et al. Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet. 2004;75:727–30. https://doi.org/10.1086/424530.CrossRefPubMedPubMedCentral

40.

Devoto M, Specchia C, Laudenslager M, Longo L, Hakonarson H, Maris J, et al. Genome-wide linkage analysis to identify genetic modifiers of ALK mutation penetrance in familial neuroblastoma. Hum Hered. 2011;71:135–9. https://doi.org/10.1159/000324843.CrossRefPubMedPubMedCentral

41.

Kamihara J, Bourdeaut F, Foulkes WD, Molenaar JJ, Mosse YP, Nakagawara A, et al. Retinoblastoma and neuroblastoma predisposition and surveillance. Clin Cancer Res. 2017;23:e98–e106. https://doi.org/10.1158/1078-0432.CCR-17-0652.CrossRefPubMedPubMedCentral

42.

Seidinger AL, Fortes FP, Mastellaro MJ, Cardinalli IA, Zambaldi LG, Aguiar SS, et al. Occurrence of neuroblastoma among TP53 p.R337H carriers. PLoS One. 2015;10:e0140356. https://doi.org/10.1371/journal.pone.0140356.CrossRefPubMedPubMedCentral

43.

Schimke RN, Collins DL, Stolle CA. Paraganglioma, neuroblastoma, and a SDHB mutation: resolution of a 30-year-old mystery. Am J Med Genet A. 2010;152A:1531–5. https://doi.org/10.1002/ajmg.a.33384.CrossRefPubMed

44.

Maas SM, Vansenne F, Kadouch DJ, Ibrahim A, Bliek J, Hopman S, et al. Phenotype, cancer risk, and surveillance in Beckwith-Wiedemann syndrome depending on molecular genetic subgroups. Am J Med Genet A. 2016;170:2248–60. https://doi.org/10.1002/ajmg.a.37801.CrossRefPubMed

45.

Kratz CP, Rapisuwon S, Reed H, Hasle H, Rosenberg PS. Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. Am J Med Genet C Semin Med Genet. 2011;157C:83–9. https://doi.org/10.1002/ajmg.c.30300.CrossRefPubMed

46.

Brems H, Beert E, de Ravel T, Legius E. Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol. 2009;10(5):508–15. https://doi.org/10.1016/S1470-2045(09)70033-6.CrossRefPubMed

47.

Rybinski B, Wolinsky T, Brohl A, Moerdler S, Reed DR, Ewart M, et al. Multifocal primary neuroblastoma tumor heterogeneity in siblings with co-occurring PHOX2B and NF1 genetic aberrations. Genes Chromosomes Cancer. 2020;59:119–24. https://doi.org/10.1002/gcc.22809.CrossRefPubMed

48.

Jones SM, Kazlauskas A. Growth-factor-dependent mitogenesis requires two distinct phases of signalling. Nat Cell Biol. 2001;3(2):165–72. https://doi.org/10.1038/35055073.CrossRefPubMed

49.

Vasjari L, Bresan S, Biskup C, Pai G, Rubio I. Ras signals principally via Erk in G1 but cooperates with PI3K/Akt for Cyclin D induction and S-phase entry. Cell Cycle. 2019;18:204–25. https://doi.org/10.1080/15384101.2018.1560205.CrossRefPubMedPubMedCentral

50.

Brady SW, Liu Y, Ma X, Gout AM, Hagiwara K, Zhou X, et al. Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations. Nat Commun. 2020;11(1):5183. https://doi.org/10.1038/s41467-020-18987-4.CrossRefPubMedPubMedCentral

51.

Edlich F. BCL-2 proteins and apoptosis: recent insights and unknowns. Biochem Biophys Res Commun. 2018;500(1):26–34. https://doi.org/10.1016/j.bbrc.2017.06.190.CrossRefPubMed

52.

Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol. 2008;10:138–48. https://doi.org/10.1038/ncb1676.CrossRefPubMedPubMedCentral

53.

Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012;149:656–70. https://doi.org/10.1016/j.cell.2012.01.058.CrossRefPubMedPubMedCentral

54.

Hall A, Meyle KD, Lange MK, Klima M, Sanderhoff M, Dahl C, et al. Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene. Oncotarget. 2013;4:584–99. https://doi.org/10.18632/oncotarget.965.CrossRefPubMedPubMedCentral

55.

Falck Miniotis M, Arunan V, Eykyn TR, Marais R, Workman P, Leach MO, et al. MEK1/2 inhibition decreases lactate in BRAF-driven human cancer cells. Cancer Res. 2013;73(13):4039–49. https://doi.org/10.1158/0008-5472.CAN-12-1969.CrossRefPubMed

56.

Kim JW, Gao P, Liu YC, Semenza GL, Dang CV. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol. 2007;27:7381–93. https://doi.org/10.1128/MCB.00440-07.CrossRefPubMedPubMedCentral

57.

Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, et al. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov. 2014;4:423–33. https://doi.org/10.1158/2159-8290.CD-13-0440.CrossRefPubMedPubMedCentral

58.

Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A. 1997;94(13):6658–63. https://doi.org/10.1073/pnas.94.13.6658.CrossRefPubMedPubMedCentral

59.

Ng HH, Surani MA. The transcriptional and signalling networks of pluripotency. Nat Cell Biol. 2011;13:490–6. https://doi.org/10.1038/ncb0511-490.CrossRefPubMed

60.

Chung J, Uchida E, Grammer TC, Blenis J. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol. 1997;17:6508–16. https://doi.org/10.1128/mcb.17.11.6508.CrossRefPubMedPubMedCentral

61.

Sengupta TK, Talbot ES, Scherle PA, Ivashkiv LB. Rapid inhibition of interleukin-6 signaling and Stat3 activation mediated by mitogen-activated protein kinases. Proc Natl Acad Sci U S A. 1998;95(19):11107–12. https://doi.org/10.1073/pnas.95.19.11107.CrossRefPubMedPubMedCentral

62.

Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol. 2004;24:6539–49. https://doi.org/10.1128/MCB.24.15.6539-6549.2004.CrossRefPubMedPubMedCentral

63.

Pelletier J, Graff J, Ruggero D, Sonenberg N. Targeting the eIF4F translation initiation complex: a critical nexus for cancer development. Cancer Res. 2015;75:250–63. https://doi.org/10.1158/0008-5472.CAN-14-2789.CrossRefPubMedPubMedCentral

64.

Lavoie H, Gagnon J, Therrien M. ERK signalling: a master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol. 2020;21(10):607–32. https://doi.org/10.1038/s41580-020-0255-7.CrossRefPubMed

65.

Hubner A, Barrett T, Flavell RA, Davis RJ. Multisite phosphorylation regulates Bim stability and apoptotic activity. Mol Cell. 2008;30:415–25. https://doi.org/10.1016/j.molcel.2008.03.025.CrossRefPubMedPubMedCentral

66.

Kennedy D, Mnich K, Oommen D, Chakravarthy R, Almeida-Souza L, Krols M, et al. HSPB1 facilitates ERK-mediated phosphorylation and degradation of BIM to attenuate endoplasmic reticulum stress-induced apoptosis. Cell Death Dis. 2017;8(8):e3026. https://doi.org/10.1038/cddis.2017.408.CrossRefPubMedPubMedCentral

67.

Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science. 1999;286:1358–62. https://doi.org/10.1126/science.286.5443.1358.CrossRefPubMed

68.

Mendoza MC, Er EE, Zhang W, Ballif BA, Elliott HL, Danuser G, et al. ERK-MAPK drives lamellipodia protrusion by activating the WAVE2 regulatory complex. Mol Cell. 2011;41:661–71. https://doi.org/10.1016/j.molcel.2011.02.031.CrossRefPubMedPubMedCentral

69.

Miki H, Fukuda M, Nishida E, Takenawa T. Phosphorylation of WAVE downstream of mitogen-activated protein kinase signaling. J Biol Chem. 1999;274(39):27605–9. https://doi.org/10.1074/jbc.274.39.27605.CrossRefPubMed

70.

Choi C, Helfman DM. The Ras-ERK pathway modulates cytoskeleton organization, cell motility and lung metastasis signature genes in MDA-MB-231 LM2. Oncogene. 2014;33(28):3668–76. https://doi.org/10.1038/onc.2013.341.CrossRefPubMed

71.

Drosten M, Dhawahir A, Sum EY, Urosevic J, Lechuga CG, Esteban LM, et al. Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J. 2010;29(6):1091–104. https://doi.org/10.1038/emboj.2010.7.CrossRefPubMedPubMedCentral

72.

Klein RM, Spofford LS, Abel EV, Ortiz A, Aplin AE. B-RAF regulation of Rnd3 participates in actin cytoskeletal and focal adhesion organization. Mol Biol Cell. 2008;19(2):498–508. https://doi.org/10.1091/mbc.e07-09-0895.CrossRefPubMedPubMedCentral

73.

Sugimoto T, Kuroda H, Horii Y, Moritake H, Tanaka T, Hattori S. Signal transduction pathways through TRK-A and TRK-B receptors in human neuroblastoma cells. Jpn J Cancer Res. 2001;92(2):152–60. https://doi.org/10.1111/j.1349-7006.2001.tb01077.x.CrossRefPubMedPubMedCentral

74.

Jones DT, Hutter B, Jager N, Korshunov A, Kool M, Warnatz HJ, et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet. 2013;45(8):927–32. https://doi.org/10.1038/ng.2682.CrossRefPubMedPubMedCentral

75.

Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141(7):1117–34. https://doi.org/10.1016/j.cell.2010.06.011.CrossRefPubMedPubMedCentral

76.

Pacenta HL, Macy ME. Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma. Drug Des Devel Ther. 2018;12:3549–61. https://doi.org/10.2147/DDDT.S147384.CrossRefPubMedPubMedCentral

77.

Prigent SA, Nagane M, Lin H, Huvar I, Boss GR, Feramisco JR, et al. Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J Biol Chem. 1996;271:25639–45. https://doi.org/10.1074/jbc.271.41.25639.CrossRefPubMed

78.

Vogel W, Ullrich A. Multiple in vivo phosphorylated tyrosine phosphatase SHP-2 engages binding to Grb2 via tyrosine 584. Cell Growth Differ. 1996;7:1589–97.PubMed

79.

Zhang J, Zhang F, Niu R. Functions of Shp2 in cancer. J Cell Mol Med. 2015;19(9):2075–83. https://doi.org/10.1111/jcmm.12618.CrossRefPubMedPubMedCentral

80.

Chan G, Kalaitzidis D, Neel BG. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev. 2008;27:179–92. https://doi.org/10.1007/s10555-008-9126-y.CrossRefPubMed

81.

Salcini AE, McGlade J, Pelicci G, Nicoletti I, Pawson T, Pelicci PG. Formation of Shc-Grb2 complexes is necessary to induce neoplastic transformation by overexpression of Shc proteins. Oncogene. 1994;9:2827–36.PubMed

82.

Bentires-Alj M, Paez JG, David FS, Keilhack H, Halmos B, Naoki K, et al. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 2004;64:8816–20. https://doi.org/10.1158/0008-5472.CAN-04-1923.CrossRefPubMed

83.

Rojas JM, Subleski M, Coque JJ, Guerrero C, Saez R, Li BQ, et al. Isoform-specific insertion near the Grb2-binding domain modulates the intrinsic guanine nucleotide exchange activity of hSos1. Oncogene. 1999;18:1651–61. https://doi.org/10.1038/sj.onc.1202483.CrossRefPubMed

84.

Overbeck AF, Brtva TR, Cox AD, Graham SM, Huff SY, Khosravi-Far R, et al. Guanine nucleotide exchange factors: activators of Ras superfamily proteins. Mol Reprod Dev. 1995;42(4):468–76. https://doi.org/10.1002/mrd.1080420415.CrossRefPubMed

85.

Kholodenko BN. Four-dimensional organization of protein kinase signaling cascades: the roles of diffusion, endocytosis and molecular motors. J Exp Biol. 2003;206(12):2073–82. https://doi.org/10.1242/jeb.00298.CrossRefPubMed

86.

Jiang X, Sorkin A. Coordinated traffic of Grb2 and Ras during epidermal growth factor receptor endocytosis visualized in living cells. Mol Biol Cell. 2002;13(5):1522–35. https://doi.org/10.1091/mbc.01-11-0552.CrossRefPubMedPubMedCentral

87.

Cichowski K, Santiago S, Jardim M, Johnson BW, Jacks T. Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor. Genes Dev. 2003;17:449–54. https://doi.org/10.1101/gad.1054703.CrossRefPubMedPubMedCentral

88.

Holzel M, Huang S, Koster J, Ora I, Lakeman A, Caron H, et al. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell. 2010;142:218–29. https://doi.org/10.1016/j.cell.2010.06.004.CrossRefPubMedPubMedCentral

89.

Buday L, Warne PH, Downward J. Downregulation of the Ras activation pathway by MAP kinase phosphorylation of Sos. Oncogene. 1995;11:1327–31.PubMed

90.

Jaitner BK, Becker J, Linnemann T, Herrmann C, Wittinghofer A, Block C. Discrimination of amino acids mediating Ras binding from noninteracting residues affecting raf activation by double mutant analysis. J Biol Chem. 1997;272:29927–33. https://doi.org/10.1074/jbc.272.47.29927.CrossRefPubMed

91.

Weber CK, Slupsky JR, Kalmes HA, Rapp UR, et al. Cancer Res. 2001;61:3595–8.PubMed

92.

Luo ZJ, Zhang XF, Rapp U, Avruch J. Identification of the 14.3.3 zeta domains important for self-association and Raf binding. J Biol Chem. 1995;270(40):23681–7. https://doi.org/10.1074/jbc.270.40.23681.CrossRefPubMed

93.

Roy S, McPherson RA, Apolloni A, Yan J, Lane A, Clyde-Smith J, et al. 14-3-3 facilitates Ras-dependent Raf-1 activation in vitro and in vivo. Mol Cell Biol. 1998;18:3947–55. https://doi.org/10.1128/mcb.18.7.3947.CrossRefPubMedPubMedCentral

94.

Tzivion G, Luo Z, Avruch J. A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity. Nature. 1998;394:88–92. https://doi.org/10.1038/27938.CrossRefPubMed

95.

Freeman AK, Ritt DA, Morrison DK. Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. Mol Cell. 2013;49(4):751–8. https://doi.org/10.1016/j.molcel.2012.12.018.CrossRefPubMedPubMedCentral

96.

Marais R, Light Y, Paterson HF, Mason CS, Marshall CJ. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem. 1997;272(7):4378–83. https://doi.org/10.1074/jbc.272.7.4378.CrossRefPubMed

97.

Schaeffer HJ, Weber MJ. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol. 1999;19(4):2435–44. https://doi.org/10.1128/mcb.19.4.2435.CrossRefPubMedPubMedCentral

98.

Lange-Carter CA, Pleiman CM, Gardner AM, Blumer KJ, Johnson GL. A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf. Science. 1993;260:315–9. https://doi.org/10.1126/science.8385802.CrossRefPubMed

99.

Posada J, Yew N, Ahn NG, Vande Woude GF, Cooper JA. Mos stimulates MAP kinase in Xenopus oocytes and activates a MAP kinase kinase in vitro. Mol Cell Biol. 1993;13:2546–53. https://doi.org/10.1128/mcb.13.4.2546.CrossRefPubMedPubMedCentral

100.

Zheng CF, Ohmichi M, Saltiel AR, Guan KL. Growth factor induced MEK activation is primarily mediated by an activator different from c-raf. Biochemistry. 1994;33:5595–9. https://doi.org/10.1021/bi00184a031.CrossRefPubMed

101.

Bogoyevitch MA, Court NW. Counting on mitogen-activated protein kinases--ERKs 3, 4, 5, 6, 7 and 8. Cell Signal. 2004;16(12):1345–54. https://doi.org/10.1016/j.cellsig.2004.05.004.CrossRefPubMed

102.

Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J. 2000;351(Pt 2):289–305.CrossRefPubMedPubMedCentral

103.

Ritt DA, Daar IO, Morrison DK. KSR regulation of the Raf-MEK-ERK cascade. Methods Enzymol. 2006;407:224–37. https://doi.org/10.1016/S0076-6879(05)07019-9.CrossRefPubMed

104.

Fukuda M, Gotoh Y, Nishida E. Interaction of MAP kinase with MAP kinase kinase: its possible role in the control of nucleocytoplasmic transport of MAP kinase. EMBO J. 1997;16:1901–8. https://doi.org/10.1093/emboj/16.8.1901.CrossRefPubMedPubMedCentral

105.

Lange DE, Rager H, Plagmann HC, Baumann M. Studies on the effectiveness of water spray devices in the gingival region. Dtsch Zahnarztl Z. 1976;31:399–404.PubMed

106.

Catling AD, Schaeffer HJ, Reuter CW, Reddy GR, Weber MJ. A proline-rich sequence unique to MEK1 and MEK2 is required for raf binding and regulates MEK function. Mol Cell Biol. 1995;15:5214–25. https://doi.org/10.1128/mcb.15.10.5214.CrossRefPubMedPubMedCentral

107.

Casar B, Pinto A, Crespo P. Essential role of ERK dimers in the activation of cytoplasmic but not nuclear substrates by ERK-scaffold complexes. Mol Cell. 2008;31:708–21. https://doi.org/10.1016/j.molcel.2008.07.024.CrossRefPubMed

108.

Khokhlatchev AV, Canagarajah B, Wilsbacher J, Robinson M, Atkinson M, Goldsmith E, et al. Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation. Cell. 1998;93(4):605–15. https://doi.org/10.1016/s0092-8674(00)81189-7.CrossRefPubMed

109.

Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors. 2006;24:21–44. https://doi.org/10.1080/02699050500284218.CrossRefPubMed

110.

Unal EB, Uhlitz F, Bluthgen N. A compendium of ERK targets. FEBS Lett. 2017;591(17):2607–15. https://doi.org/10.1002/1873-3468.12740.CrossRefPubMed

111.

Chevet E, Wong HN, Gerber D, Cochet C, Fazel A, Cameron PH, et al. Phosphorylation by CK2 and MAPK enhances calnexin association with ribosomes. EMBO J. 1999;18:3655–66. https://doi.org/10.1093/emboj/18.13.3655.CrossRefPubMedPubMedCentral

112.

Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291–310. https://doi.org/10.1038/sj.onc.1210422.CrossRefPubMed

113.

Sa G, Murugesan G, Jaye M, Ivashchenko Y, Fox PL. Activation of cytosolic phospholipase A2 by basic fibroblast growth factor via a p42 mitogen-activated protein kinase-dependent phosphorylation pathway in endothelial cells. J Biol Chem. 1995;270:2360–6. https://doi.org/10.1074/jbc.270.5.2360.CrossRefPubMed

114.

She QB, Chen N, Dong Z. ERKs and p38 kinase phosphorylate p53 protein at serine 15 in response to UV radiation. J Biol Chem. 2000;275:20444–9. https://doi.org/10.1074/jbc.M001020200.CrossRefPubMed

115.

Shapiro PS, Whalen AM, Tolwinski NS, Wilsbacher J, Froelich-Ammon SJ, Garcia M, et al. Extracellular signal-regulated kinase activates topoisomerase IIalpha through a mechanism independent of phosphorylation. Mol Cell Biol. 1999;19:3551–60. https://doi.org/10.1128/mcb.19.5.3551.CrossRefPubMedPubMedCentral

116.

Lake D, Correa SA, Muller J. Negative feedback regulation of the ERK1/2 MAPK pathway. Cell Mol Life Sci. 2016;73:4397–413. https://doi.org/10.1007/s00018-016-2297-8.CrossRefPubMedPubMedCentral

117.

Mosse YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet Oncol. 2013;14(6):472–80. https://doi.org/10.1016/S1470-2045(13)70095-0.CrossRefPubMedPubMedCentral

118.

Hallberg B, Palmer RH. The role of the ALK receptor in cancer biology. Ann Oncol. 2016;27(Suppl 3):iii4–iii15.CrossRefPubMed

119.

Umapathy G, Mendoza-Garcia P, Hallberg B, Palmer RH. Targeting anaplastic lymphoma kinase in neuroblastoma. APMIS. 2019;127(5):288–302. https://doi.org/10.1111/apm.12940.CrossRefPubMedPubMedCentral

120.

Alam MW, Borenäs M, Lind DE, Cervantes-Madrid D, Umapathy G, Palmer RH, et al. Alectinib, an anaplastic lymphoma kinase inhibitor, abolishes ALK activity and growth in ALK-positive neuroblastoma cells. Front Oncol. 2019;9:579.CrossRefPubMedPubMedCentral

121.

Bresler SC, Wood AC, Haglund EA, Courtright J, Belcastro LT, Plegaria JS, et al. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med. 2011;3(108):108ra114.CrossRefPubMedPubMedCentral

122.

Cox AD, Der CJ, Philips MR. Targeting RAS membrane association: back to the future for anti-RAS drug discovery? Clin Cancer Res. 2015;21:1819–27. https://doi.org/10.1158/1078-0432.CCR-14-3214.CrossRefPubMedPubMedCentral

123.

Kakodkar NC, Peddinti RR, Tian Y, Guerrero LJ, Chlenski A, Yang Q, et al. Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth. Pediatr Blood Cancer. 2012;59(4):642–7. https://doi.org/10.1002/pbc.24004.CrossRefPubMed

124.

Okada K, Nakano Y, Yamasaki K, Nitani C, Fujisaki H, Hara J. Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases. Cancer Med. 2016;5:1947–9. https://doi.org/10.1002/cam4.784.CrossRefPubMedPubMedCentral

125.

Umapathy G, Guan J, Gustafsson DE, Javanmardi N, Cervantes-Madrid D, Djos A, et al. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas. Sci Signal. 2017;10. https://doi.org/10.1126/scisignal.aam7550.

126.

Woodfield SE, Zhang L, Scorsone KA, Liu Y, Zage PE. Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression. BMC Cancer. 2016;16(1):172. https://doi.org/10.1186/s12885-016-2199-z.CrossRefPubMedPubMedCentral

127.

Hart LS, Rader J, Raman P, Batra V, Russell MR, Tsang M, et al. Preclinical therapeutic synergy of MEK1/2 and CDK4/6 inhibition in neuroblastoma. Clin Cancer Res. 2017;23(7):1785–96. https://doi.org/10.1158/1078-0432.CCR-16-1131.CrossRefPubMed

128.

Takeuchi Y, Tanaka T, Higashi M, Fumino S, Iehara T, Hosoi H, et al. In vivo effects of short- and long-term MAPK pathway inhibition against neuroblastoma. J Pediatr Surg. 2018;53:2454–9. https://doi.org/10.1016/j.jpedsurg.2018.08.026.CrossRefPubMed

129.

Ishii N, Harada N, Joseph EW, Ohara K, Miura T, Sakamoto H, et al. Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity. Cancer Res. 2013;73(13):4050–60. https://doi.org/10.1158/0008-5472.CAN-12-3937.CrossRefPubMedPubMedCentral

130.

Valencia-Sama I, Ladumor Y, Kee L, Adderley T, Christopher G, Robinson CM, et al. NRAS status determines sensitivity to SHP2 inhibitor combination therapies targeting the RAS-MAPK pathway in neuroblastoma. Cancer Res. 2020;80:3413–23. https://doi.org/10.1158/0008-5472.CAN-19-3822.CrossRefPubMed

131.

King D, Yeomanson D, Bryant HE. PI3King the lock: targeting the PI3K/Akt/mTOR pathway as a novel therapeutic strategy in neuroblastoma. J Pediatr Hematol Oncol. 2015;37:245–51. https://doi.org/10.1097/MPH.0000000000000329.CrossRefPubMed

132.

Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011;36:320–8. https://doi.org/10.1016/j.tibs.2011.03.006.CrossRefPubMedPubMedCentral

133.

Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, et al. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell. 2012;22:117–30. https://doi.org/10.1016/j.ccr.2012.06.001.CrossRefPubMedPubMedCentral

134.

Moore NF, Azarova AM, Bhatnagar N, Ross KN, Drake LE, Frumm S, et al. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. Oncotarget. 2014;5:8737–49. https://doi.org/10.18632/oncotarget.2372.CrossRefPubMedPubMedCentral

135.

Rader J, Russell MR, Hart LS, Nakazawa MS, Belcastro LT, Martinez D, et al. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013;19:6173–82. https://doi.org/10.1158/1078-0432.CCR-13-1675.CrossRefPubMed

136.

Wood AC, Krytska K, Ryles HT, Infarinato NR, Sano R, Hansel TD, et al. Dual ALK and CDK4/6 inhibition demonstrates synergy against neuroblastoma. Clin Cancer Res. 2017;23:2856–68. https://doi.org/10.1158/1078-0432.CCR-16-1114.CrossRefPubMed

137.

Wang HQ, Halilovic E, Li X, Liang J, Cao Y, Rakiec DP, et al. Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models. Elife. 2017;6. https://doi.org/10.7554/eLife.17137.

138.

Coggins GE, Farrel A, Rathi KS, Hayes CM, Scolaro L, Rokita JL, et al. YAP1 mediates resistance to MEK1/2 inhibition in neuroblastomas with hyperactivated RAS signaling. Cancer Res. 2019;79:6204–14. https://doi.org/10.1158/0008-5472.CAN-19-1415.CrossRefPubMedPubMedCentral

139.

Subramonian D, Phanhthilath N, Rinehardt H, Flynn S, Huo Y, Zhang J, et al. Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways. Br J Cancer. 2020;123:568–79. https://doi.org/10.1038/s41416-020-0905-8.CrossRefPubMedPubMedCentral

Title: A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma
Authors: Vid Mlakar
Edouard Morel
Simona Jurkovic Mlakar
Marc Ansari
Fabienne Gumy-Pause
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Neuroblastoma
Neuroblastoma
Alectinib
Ceritinib
Crizotinib
Lorlatinib
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-021-01967-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

SLC6A8-mediated intracellular creatine accumulation enhances hypoxic breast cancer cell survival via ameliorating oxidative stress

Down-regulation of the tumor suppressor miR-34a contributes to head and neck cancer by up-regulating the MET oncogene and modulating tumor immune evasion

Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression

Hsa_circ_0004296 inhibits metastasis of prostate cancer by interacting with EIF4A3 to prevent nuclear export of ETS1 mRNA

A review of Dynamin 2 involvement in cancers highlights a promising therapeutic target

RETRACTED ARTICLE: Ethaselen synergizes with oxaliplatin in tumor growth inhibition by inducing ROS production and inhibiting TrxR1 activity in gastric cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer